Thymalin

ID: thymalin

Aliases: THYMALIN, Timalin, thymic peptide extract

Type: compound

Route/form: regional injectable thymic peptide/extract context; no approved US route

Status: regional_or_research

Evidence level: early human

Best data tier: early human

Support scope: human, review/regulatory

Source types: early_human, review

Linked sources: 3

Broad outcomes: Gut / immune / inflammation, Longevity / mitochondrial / redox

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• thymic peptide immunomodulation
• T-cell/immune aging hypotheses
• geroprotector claims in older regional literature

Optimization domains

• immune
• longevity
• aging
• thymus

Research basis

• Older human/regional literature discusses thymic peptide bioregulators and longevity/immune outcomes.

Limits, risks, and missing evidence

• Evidence quality and modern replication are major limitations.
• Should not be collapsed with thymosin alpha-1, which has a different evidence base and molecule identity.

Risk flags

• regional bioregulator literature
• weak human context
• immune modulation
• identity uncertain

Linked papers, labels, and reviews

1. Peptides of pineal gland and thymus prolong human life
   early_human / pubmed_thymalin_longevity_2003
   Older regional longevity report; hypothesis-generating, not definitive geroprotection evidence.
2. Geroprotective effect of thymalin and epithalamin
   review / pubmed_thymalin_geroprotective_2002
   Older thymic/pineal peptide bioregulator background.
3. Peptides and ageing
   review / pubmed_short_peptides_ageing_2002
   Broad Russian peptide-bioregulator review; useful background but low specificity for named peptide products.